GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Guobang Pharma 605507.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

15.55

-1.02%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥6.01bn

FY2017FY2025

Net income

CN¥820.8m

FY2017FY2025

Free cash flow

CN¥281.6m

FY2017FY2025

Shareholders' equity

CN¥8.55bn

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueCN¥6.01bnCN¥5.89bnCN¥5.35bnCN¥5.72bnCN¥4.51bnCN¥4.21bnCN¥3.80bnCN¥3.28bnCN¥2.91bn
Gross profitCN¥2.04bnCN¥1.44bnCN¥1.21bnCN¥1.53bnCN¥1.29bnCN¥1.41bnCN¥963.2mCN¥919.7mCN¥821.8m
Research and developmentCN¥209.8mCN¥215.5mCN¥190.5mCN¥197.5mCN¥155.3mCN¥137.2mCN¥124.3mCN¥103.3mCN¥94.7m
Operating incomeCN¥961.9mCN¥895.1mCN¥702.3mCN¥1.05bnCN¥808.8mCN¥969.5mCN¥581.6mCN¥579.7mCN¥469.3m
Net incomeCN¥820.8mCN¥781.6mCN¥612.5mCN¥920.9mCN¥706.0mCN¥810.0mCN¥314.9mCN¥210.9mCN¥177.7m
Diluted earnings per share1.481.401.101.651.271.710.570.380.32

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsCN¥10.98bnCN¥10.78bnCN¥10.36bnCN¥9.04bnCN¥7.51bnCN¥5.51bnCN¥4.76bnCN¥4.37bnCN¥4.02bn
Cash and short-term investments—CN¥2.53bnCN¥2.56bnCN¥2.80bnCN¥2.15bnCN¥1.23bnCN¥1.26bnCN¥1.00bnCN¥946.1m
Total liabilitiesCN¥2.43bnCN¥2.73bnCN¥2.92bnCN¥1.89bnCN¥1.17bnCN¥2.23bnCN¥2.14bnCN¥1.77bnCN¥1.82bn
DebtCN¥478.0mCN¥321.9mCN¥934.4mCN¥655.6mCN¥160.2mCN¥910.7mCN¥900.6mCN¥608.1mCN¥698.0m
Shareholders' equityCN¥8.55bnCN¥8.05bnCN¥7.43bnCN¥7.16bnCN¥6.35bnCN¥3.27bnCN¥2.62bnCN¥1.25bnCN¥1.08bn
Shares outstanding553m558m559m559m557m475m553m553m553m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operationsCN¥559.3mCN¥706.4mCN¥516.8mCN¥1.02bn−CN¥176.2mCN¥767.7mCN¥440.9mCN¥541.7mCN¥148.0m
Capital spending−CN¥277.7m−CN¥419.1m−CN¥748.4m−CN¥803.1m−CN¥448.0m−CN¥520.2m−CN¥605.2m−CN¥163.2m−CN¥169.5m
Free cash flowCN¥281.6mCN¥287.3m−CN¥231.7mCN¥213.9m−CN¥624.2mCN¥247.5m−CN¥164.3mCN¥378.4m−CN¥21.4m
Dividends paid−CN¥359.6m−CN¥194.1m−CN¥361.6m−CN¥111.8m−CN¥279.4m−CN¥152.0m−CN¥34.1m−CN¥31.3m−CN¥46.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥1.62bnCN¥1.52bnCN¥1.54bnCN¥1.44bnCN¥1.59bnCN¥1.44bnCN¥1.47bnCN¥1.53bn
Gross profitCN¥396.3mCN¥350.8mCN¥362.4mCN¥389.8mCN¥423.0mCN¥380.7mCN¥279.2mCN¥435.5m
Operating incomeCN¥212.3mCN¥216.5mCN¥202.2mCN¥226.5mCN¥273.6mCN¥248.5mCN¥138.8mCN¥201.5m
Net incomeCN¥180.7mCN¥160.6mCN¥150.6mCN¥214.7mCN¥240.6mCN¥215.0mCN¥202.7mCN¥174.3m
Diluted earnings per share0.330.290.270.390.440.390.360.31
Cash from operations———CN¥311.0mCN¥454.0m−CN¥348.0mCN¥673.0mCN¥283.0m
Capital spending−CN¥236.0m−CN¥91.0m−CN¥10.0m−CN¥110.0m−CN¥115.0m−CN¥41.0m−CN¥214.0m−CN¥32.0m
Free cash flow———CN¥201.0mCN¥339.0m−CN¥389.0mCN¥459.0mCN¥251.0m
Total assetsCN¥11.38bnCN¥11.40bnCN¥10.98bnCN¥10.58bnCN¥10.81bnCN¥11.11bnCN¥10.78bnCN¥10.63bn
Cash and short-term investments———CN¥2.21bnCN¥2.25bnCN¥2.33bnCN¥2.53bnCN¥2.16bn
DebtCN¥176.6mCN¥82.9mCN¥478.0mCN¥1.10bnCN¥945.7mCN¥710.5mCN¥321.9mCN¥528.9m
Shareholders' equityCN¥8.40bnCN¥8.71bnCN¥8.55bnCN¥8.27bnCN¥8.06bnCN¥8.26bnCN¥8.05bnCN¥7.84bn

Financial ratios

Data as of 30 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin34.0%24.4%22.6%26.8%28.7%33.4%
Operating margin16.0%15.2%13.1%18.4%18.0%23.0%
Net margin13.7%13.3%11.4%16.1%15.7%19.3%
Return on equity9.6%9.7%8.2%12.9%11.1%24.7%
Return on assets7.5%7.3%5.9%10.2%9.4%14.7%
Free cash flow yield8.4%11.1%12.5%18.0%2.7%15.0%
Revenue growth2.0%10.1%-6.5%27.0%7.1%10.6%
Earnings growth5.0%27.6%-33.5%30.4%-12.8%157.2%
Current ratio3.18x2.30x2.22x2.75x3.96x1.46x
Debt to equity0.06x0.04x0.13x0.09x0.03x0.23x
Equity ratio77.9%74.6%71.7%79.1%84.5%59.4%
Interest coverage40.21x27.47x25.50x52.45x25.31x20.61x
R&D as a share of sales3.5%3.7%3.6%3.5%3.4%3.3%
Buybacks as a share of market value0.9%0.1%0.0%-0.4%-17.3%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.7%7.4%—
Operating income-3.0%-0.2%—
Net income-3.8%0.3%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin29.2%27.1%28.1%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings16.714.916.016.122.7
Price to sales2.32.01.82.63.6

Dividends and splits

Per share, in the currency the company pays

Paid for 5 years. Last went ex-dividend on 29 May 2026.

FY2026FY2025FY2024FY2023FY2022FY2021
Paid in the year0.4290.6060.3020.600.200.50

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.